Clinical Trial Update: A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports on a phase 1/2 study of Intismeran Autogene (V940) with pembrolizumab for bladder cancer. The study is currently active but n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer

Drugs mentioned

• Intismeran Autogene (V940) (V940)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Bladder Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING